Is Biontech SE halal to invest in?

According to Musaffa's Shariah screening methodology, Biontech SE (BNTX) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Biontech SE a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Biontech SE using these criteria to determine its compliance status.

Can Muslims buy shares of Biontech SE?

Muslim investors may consider investing in Biontech SE if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Biontech SE classified as NOT HALAL?

Musaffa determines the Shariah status of Biontech SE by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Biontech SE updated?

The Shariah compliance status of Biontech SE may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Biontech SE become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Biontech SE?

You can check the latest Shariah compliance status of Biontech SE on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

BNTX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 26, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Biontech SE (BNTX)

Based on 28 analysts giving stock ratings to Biontech SE in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Biontech SE. Stock Analysis BNTX

United States Health Care Large Cap Report: 2025 Annual

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Key Statistics of Biontech SE (BNTX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$88.55$91.12

Today's Open

$90.30

Volume

1.17M

P/E Ratio (TTM)

52 Week Range

$79.52$124.00

Market Cap

24.97B

Avg. Volume

922.79K

Dividend Yield

Financial Metrics & Statements of Biontech SE (BNTX)

FAQ's for Biontech SE (BNTX)

According to Musaffa’s Shariah screening methodology, Biontech SE (BNTX) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.